$DXC

DXC Technology Co (DXC): Results of Operations and Financial Condition

DXC Technology Co (DXC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dxcfy27q1pressrelease.htm EX-99.1 Document Exhibit 99.1 DXC Technology Reports First Quarter Fiscal Year 2027 Results • Total revenue for Q1 FY27 of $3.00 billion, down 5.1% YoY, down 6.7% on an organic basis (1) • Q1 FY27 Bookings of $3.0 billion, up 5% YoY with a book

Original reporting
Published Jul 30, 2026, 8:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$DXC
Neutral
medium confidence
Mentioned
$DXC
Relevance
9/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DXCNeutralMed
01

Why it matters

Traders can update models using the provided Q1 performance and the explicit FY27 and Q2 guidance ranges, while separately assessing the contribution of litigation-related cash proceeds to free cash flow.

02

Market read

This is a primary earnings-and-guidance disclosure with specific revenue, EPS, margin, bookings, and free cash flow numbers, plus segment-level booking/profit divergence.

03

What to watch

Bookings dynamics are mixed by segment (GIS bookings up with revenue down; CES bookings down), which can foreshadow future revenue conversion and margin volatility beyond the current quarter.

Relevance 9/10Novelty 8/10Timing: after-hours filing on July 30, 2026, with Q1 FY27 results and full-year guidance ranges

Background

DXC filed an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Q1 fiscal 2027 results and guidance for FY27 and Q2 FY27.

Company-level read

Ticker impact

$DXCNeutralMedium confidence
Context

DXC reported Q1 FY27 results and reiterated full-year guidance, including revenue, EPS, free cash flow, and updated margin outlook.

Expected impact

Near-term repricing risk is moderate, with focus on whether investors discount litigation cash and organic revenue weakness versus maintained guidance.

Evidence & confidence

The filing includes concrete Q1 metrics (revenue down 5.1% YoY, non-GAAP EPS down 41.2% YoY, FCF $314M) plus full-year ranges (revenue $12.10B-$12.35B, adjusted EBIT margin 6.0%-7.0%, non-GAAP EPS $2.40-$2.90). The guidance is maintained, but the quality of FCF is partly litigation-driven, which can create mixed market interpretation.

Market effects

Signals demand and margin pressure in IT services, with GIS weakness offset by Insurance segment profit growth and bookings mix.

Primarily US-listed earnings impact; no explicit regional macro drivers beyond FX assumptions in guidance.

Guidance includes FX assumptions and global enterprise/public sector demand indicators via bookings and segment performance.

Counterpoint

Investors may treat litigation-related cash proceeds as non-recurring and focus on organic revenue decline and adjusted EBIT margin pressure rather than headline free cash flow.

Key entities

  • DXC Technology

    Reported Q1 FY27 results, segment performance, and maintained full-year guidance ranges in an SEC 8-K.

  • Raul Fernandez

    CEO quoted stating results were in line with expectations and full-year guidance is maintained.

  • Paul Taylor

    Incoming President mentioned as strengthening leadership for execution speed and focus.

Related articles

$DXCMedAI 8/10

DXC (DXC) Q1 2027 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Roger Sachs President and Chief Executive Officer - Raul J. Fernandez Chief Financial Officer - Robert F. Del Bene TAKEAWAYS Total Revenue -- $3 billion, representing a 6.7% organic decline year over year. Adjusted EBIT Margin -- 5.0%, a decrease of 180 basis points year over year reflecting the anticipated revenue profile and seasonal factors.

$DXCMedAI 8/10

DXC’s (NYSE:DXC) Q2 CY2026 Earnings Results: Non

IT services provider DXC Technology (NYSE: DXC) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 5.1% year on year to $3.00 billion. On the other hand, next quarter’s revenue guidance of $2.99 billion was less impressive, coming in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.40 per share was 11.3% below analysts’ consensus estimates. Is now the time to buy DXC? Find out by accessing our full research report, it’s free.

$DXCMed

Why is DXC Technology stock rallying today? By Investing.com

DXC Technology shares rose about 4.3% after the company said it partnered with ElevenLabs and participated in ElevenLabs’ $500 million Series D, valuing the AI firm at about $11 billion, according to DXC’s July 28, 2026 press release. The collaboration targets voice AI for service desk, training, and customer service. DXC’s Q1 FY2027 earnings are due July 30.

$DXCMed

DXC launches Private Cloud+ for regulated workloads

DXC Technology launched DXC Private Cloud+, a hybrid private cloud platform for regulated workloads in enterprises and government agencies. It runs on Dell infrastructure and is orchestrated via DXC OASIS, with options for multi-tenant consumption, single-tenant dedicated, and a government edition. DXC targets sectors like financial services, healthcare, manufacturing and public sector; service is generally available.